Updates in the Treatment of Mantle Cell Lymphoma

home / scientific-interchange-and-workshop / updates-in-the-treatment-of-mantle-cell-lymphoma

Bijal Shah, MD, MS, of Moffitt Cancer Center

EP. 1: Dr. Shah on Shortcomings With BTK Inhibitors in High-Risk MCL

By Bijal Shah, MD, Moffit Cancer Center

June 3rd 2021

Bijal Shah, MD, MS, discusses shortcomings with BTK inhibitors in high-risk mantle cell lymphoma.

EP. 2: Dr. Shah on Efforts to Combat Resistance to BTK Inhibitors in MCL

By Bijal Shah, MD, Moffit Cancer Center

July 7th 2021

Bijal Shah, MD, MS, discusses efforts to combat resistance to BTK inhibitors in patients with mantle cell lymphoma.

EP. 3: Updates in the Treatment of Mantle Cell Lymphoma

July 16th 2021

This article discusses the current treatment landscape and therapeutic strategies for mantle cell lymphoma, the role of Bruton tyrosine kinase inhibitor therapies in MCL, and insights on new regimens and ongoing clinical trials from leading experts in hematologic malignancies.